Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.

@article{Brenner2004PhaseIT,
  title={Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.},
  author={Baruch Brenner and David H. Ilson and Bruce Daniel Minsky and Manjit S. Bains and William Tong and Mithat Gonen and David Paul Kelsen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 1},
  pages={45-52}
}
PURPOSE To define the maximum-tolerated dose (MTD) of paclitaxel when given as a weekly 96-hour infusion with cisplatin and radiotherapy for patients with esophageal cancer. PATIENTS AND METHODS Thirty-four patients with locally advanced esophageal cancer and three patients with local recurrence or positive resection margins were treated. Weekly paclitaxel doses of 10, 20, 30, 40, 60, and 80 mg/m(2), given as a continuous 96-hour infusion, were administered with weekly cisplatin, 30 mg/m(2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

The Effect of Neoadjuvant Therapy on Early Complications of Esophageal Cancer Surgery

Iranian journal of otorhinolaryngology • 2015
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…